Cullinan Therapeutics initiated with a Buy at Guggenheim

Guggenheim last night initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $30 price target The firm sees a good entry point early into an “important year” of Phase 1 data catalysts for Cullinan’s T-cell engagers in autoimmune diseases and acute myeloid leukemia. CLN-049 already has preliminary efficacy data that match the benchmarks of approved AML drugs, and the second half of 2026 data update could confirm that signal, with potential for rapid pivotal development, the analyst tells investors in a research note.